US 12,030,939 B2
Bispecific antibody binding BCMA and CD3
Qiang Li, Shanghai (CN); Shixiang Jia, Shanghai (CN); Lili Zhao, Linyi (CN); Guimin Zhang, Linyi (CN); Zhong Liu, Linyi (CN); Xinlu Ma, Shanghai (CN); Yuan Yan, Shanghai (CN); Zhenyu Li, Linyi (CN); Xingxia Hu, Linyi (CN); Yuhua Zhang, Shanghai (CN); and Bin Li, Linyi (CN)
Assigned to Shandong New Time Pharmaceutical Co., Ltd., Shandong (CN)
Appl. No. 17/290,401
Filed by SHANDONG NEW TIME PHARMACEUTICAL CO., LTD., Shandong (CN)
PCT Filed Sep. 26, 2019, PCT No. PCT/CN2019/108057
§ 371(c)(1), (2) Date Apr. 30, 2021,
PCT Pub. No. WO2020/088164, PCT Pub. Date May 7, 2020.
Claims priority of application No. 201811294887.4 (CN), filed on Nov. 1, 2018.
Prior Publication US 2023/0416385 A1, Dec. 28, 2023
Int. Cl. C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C07K 16/46 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C07K 16/3007 (2013.01); C07K 16/303 (2013.01); C07K 16/32 (2013.01); C07K 16/468 (2013.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A bispecific antibody, which is composed of two identical polypeptide chains bonded covalently to form a tetravalent homodimer,
wherein each of the polypeptide chains has the amino acid sequence as set forth in SEQ ID NO: 20,
wherein each of the polypeptide chains consists of an anti-BCMA (B cell maturation antigen) scFv, a linker peptide L2, an anti-CD3 scFv, and an Fc fragment in order,
wherein VH (heavy chain variable region) and VL (light chain variable region) within the anti-BCMA scFv and the anti-CD3 scFv are connected by a linker sequence respectively, and wherein the amino acid sequence of the linker sequence is amino acids 3-17 of SEQ ID NO: 10,
wherein the amino acid sequences of the VH and the VL of the anti-BCMA scFv are SEQ ID NO: 7 and SEQ ID NO: 8, respectively,
wherein the amino acid sequences of the VH and the VL of the anti-CD3 scFv are SEQ ID NO: 17 and SEQ ID NO: 18, respectively,
wherein the linker peptide L2 consists of a flexible peptide and a rigid peptide,
wherein the amino acid sequence of the flexible peptide is SEQ ID NO: 29 G2, and
wherein the amino acid sequence of the rigid peptide is SEQ ID NO: 24.